Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 3/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.66 |
| ▸ | MAPT | P10636 | 2/20 | 0.66 |
| ▸ | HPGD | P15428 | 2/20 | 0.66 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.66 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.66 |
| ▸ | EGFR | P00533 | 1/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | PRKCG | P05129 | 1/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.66 |
| ▸ | PRKCB | P05771 | 1/20 | 0.66 |
| ▸ | POLB | P06746 | 1/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.66 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.66 |
| ▸ | THRB | P10828 | 1/20 | 0.66 |
| ▸ | PRKCA | P17252 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Daphnetin SCHEMBL128212 | 0.79 | MCL1 (1.00) | MCL1KDM4EALDH1A1MAPTHPGD | |
| Daphnetin SCHEMBL29612544 | 0.79 | MCL1 (1.00) | MCL1KDM4EALDH1A1MAPTHPGD | |
| SCHEMBL8750107 | 0.79 | ALDH1A1 (0.48) | MCL1KDM4EALDH1A1MAPTHPGD | |
| Daphnetin SCHEMBL29041019 | 0.78 | MCL1 (0.96) | MCL1KDM4EALDH1A1MAPTHPGD | |
| SCHEMBL4178181 | 0.76 | MCL1 (0.66) | MCL1KDM4EALDH1A1MAPTHPGD | |
| Daphnetin SCHEMBL28751158 | 0.76 | MCL1 (0.92) | MCL1KDM4EALDH1A1MAPTHPGD | |
| Daphnetin SCHEMBL28897878 | 0.76 | MCL1 (0.92) | MCL1KDM4EALDH1A1MAPTHPGD | |
| SCHEMBL31004966 | 0.76 | CA9 (1.00) | MCL1KDM4EALDH1A1MAPTHPGD | |
| SCHEMBL11434277 | 0.76 | CA9 (1.00) | MCL1KDM4EALDH1A1MAPTHPGD | |
| SCHEMBL30599780 | 0.76 | CA9 (1.00) | MCL1KDM4EALDH1A1MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-56040601-A | — | — | None | — | — | JP | disclosed |
| US-8080565-B2 | Substituted 4-amino-benzylpiperidine compounds | THERAVANCE, INC. (US) | 2011-12-20 | — | — | US | disclosed |
| US-20090023777-A1 | Substituted 4-amino-benzylpiperidine compounds | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-01-22 | — | — | US | disclosed |
| US-7368463-B2 | Substituted 4-amino-1-benzylpiperidine compounds | THERAVANCE, INC. (US) | 2008-05-06 | — | — | US | disclosed |
| CN-101074222-A | 3-substituted cumarin compound, its production, medicinal composition and use | DRUG INST CHINA ACADEMY OF MED (CN) | 2007-11-21 | — | — | CN | disclosed |
| US-20050026954-A1 | Muscarinic receptor antagonists; overactive bladder, irritable bowel syndrome, chronic obstructive pulmonary disease, and asthma | THERAVANCE BIOPHARMA R&D IP, LLC | 2005-02-03 | — | — | US | disclosed |
| JP-2004055631-A | ELECTROLYTE FOR DRIVING ELECTROLYTIC CAPACITOR | NICHICON CORP | 2004-02-19 | — | — | JP | disclosed |
| US-6251644-B1 | MIXING SOLUTION OR SUPSENSION WITH PHOTOSENSITIZER OF SPECIFIC STRUCTURE, ADJUSTING OPERATING CONDITION TO INCREASE PERMEABILITY OF VIRUS, THEN IRRADIATING WITH ULTRAVIOLET, VISIBLE, OR IONIZING RADIATION | BAXTER INTERNATIONAL, INC. | 2001-06-26 | — | — | US | disclosed |
| US-6169109-B1 | MIXING ONE OF A NOVEL CLASS OF PSORALEN PHOTOSENSITIZERS WITH SAID SOLUTION AND IRRADIATING THE MIXTURE | BAXTER INTERNATIONAL INC. | 2001-01-02 | — | — | US | disclosed |
| EP-0782388-A4 | PHOTODYNAMIC INACTIVATION OF VIRAL AND BACTERIAL BLOOD CONTAMINANTS WITH HALOGENATED COUMARIN AND FUROCOUMARIN SENSITIZERS | BAXTER INT (US) | 2000-03-08 | — | — | EP | disclosed |
| US-5789601-A | MIXING WITH PHOTOSENSITIZER AND RADIATION | BAXTER INTERNATIONAL INC. (US) | 1998-08-04 | — | — | US | disclosed |
| EP-0782388-A1 | PHOTODYNAMIC INACTIVATION OF VIRAL AND BACTERIAL BLOOD CONTAMINANTS WITH HALOGENATED COUMARIN AND FUROCOUMARIN SENSITIZERS | BAXTER INTERNATIONAL INC. (US) | 1997-07-09 | — | — | EP | disclosed |
| US-5516629-A | Photoinactivation of viral and bacterial blood contaminants using halogenated coumarins | CRYOPHARM CORPORATION (US) | 1996-05-14 | — | — | US | disclosed |
| WO-1996008965-A1 | PHOTODYNAMIC INACTIVATION OF VIRAL AND BACTERIAL BLOOD CONTAMINANTS WITH HALOGENATED COUMARIN AND FUROCOUMARIN SENSITIZERS | BAXTER INTERNATIONAL, INC. (US) | 1996-03-28 | — | — | WO | disclosed |
| US-5216176-A | 7-alkoxycoumarins, dihydropsoralens, and benzodipyranones as photo-activated therapeutic agents and inhibitors of epidermal growth factor | LEHIGH UNIVERSITY (US) | 1993-06-01 | — | — | US | disclosed |
| EP-0467318-A1 | Fluorogenic tryptophanase substrates | Becton, Dickinson and Company (US) | 1992-01-22 | — | — | EP | disclosed |
| WO-1990008529-A2 | 7-ALKOXYCOUMARINS, DIHYDROPSORALENS, AND BENZODIPYRANONES AS PHOTO-ACTIVATED THERAPEUTIC AGENTS AND INHIBITORS OF EPIDERMAL GROWTH FACTOR | LEHIGH UNIVERSITY (US) | 1990-08-09 | — | — | WO | disclosed |
| JP-S5640601-A | DEPOSITION INHIBITOR FOR LIVING THING IN WATER | NIPPON PAINT CO LTD | 1981-04-16 | — | — | JP | disclosed |
| US-4235781-A | 6 Or 8 Haloallyl substituted 7-hydroxycoumarins | THOMAS C. ELDER, INC. (US) | 1980-11-25 | — | — | US | disclosed |
| US-4216154-A | CLAISEN REARRANGEMENT OF A 7-HALOALLYL ETHER OF A HYDROXYCOUMARIN | THOMAS C. ELDER, INC. (US) | 1980-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026954-A1 | Muscarinic receptor antagonists; overactive bladder, irritable bowel syndrome, chronic obstructive pulmonary disease, and asthma | CHRM5, CHRM3, CHRM1 | MCL1 4192/4885KDM4E 1655/4885ALDH1A1 1154/4885 |
| US-20090023777-A1 | Substituted 4-amino-benzylpiperidine compounds | CHRM5, CHRM3, GPR4 | MCL1 4012/4885KDM4E 734/4885ALDH1A1 1245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.